New CRISPR Technique Selectively Shreds Cancer Cells, Including “Undruggable” Cancers
16th June 2026
The job of a tumor suppressor protein is right in the name: stopping us from getting cancer at the cellular level. But when they’re not working properly, the cell is left with limited defenses.
In a new paper published today in the journal Nature titled “Targeting Cancer-Specific Mutations with RNA-Triggered Chromatin Shredding,“ researchers at the Innovative Genomics Institute (IGI) at UC Berkeley, UC San Francisco, and Gladstone Institutes, along with collaborators at University of Utah and Utah State University, report that a creative new CRISPR-based approach can selectively destroy cells carrying a mutation in a tumor suppressor found in nearly half of all cancers and up to 70–90% of cases of some of the most difficult-to-treat cancers, including ovarian, pancreatic, and non-small cell lung cancer.
“Not only can this approach target the ‘undruggable’ cancers that we know, we can also easily and quickly adapt this to new mutations,” says IGI Founder Jennifer Doudna, a co-author on the paper. “This is an exciting development for cancer therapies, and potentially for other applications as well.”